138 related articles for article (PubMed ID: 14584798)
21. Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy.
Angenault S; Thirot S; Schmidt F; Monneret C; Pfeiffer B; Renard P
Bioorg Med Chem Lett; 2003 Mar; 13(5):947-50. PubMed ID: 12617927
[TBL] [Abstract][Full Text] [Related]
22. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Abu Ajaj K; Unger C; Warnecke A; Saleem T; El-Melegy N; Madkor H; Kratz F
Eur J Cancer; 2010 Dec; 46(18):3434-44. PubMed ID: 20933385
[TBL] [Abstract][Full Text] [Related]
23. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin.
Dubowchik GM; Mosure K; Knipe JO; Firestone RA
Bioorg Med Chem Lett; 1998 Dec; 8(23):3347-52. PubMed ID: 9873732
[TBL] [Abstract][Full Text] [Related]
24. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.
Heinis C; Alessi P; Neri D
Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213
[TBL] [Abstract][Full Text] [Related]
25. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
26. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
27. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs.
Abu Ajaj K; Biniossek ML; Kratz F
Bioconjug Chem; 2009 Feb; 20(2):390-6. PubMed ID: 19199576
[TBL] [Abstract][Full Text] [Related]
28. A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel.
Hayashi Y; Skwarczynski M; Hamada Y; Sohma Y; Kimura T; Kiso Y
J Med Chem; 2003 Aug; 46(18):3782-4. PubMed ID: 12930140
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug.
Rodrigues ML; Carter P; Wirth C; Mullins S; Lee A; Blackburn BK
Chem Biol; 1995 Apr; 2(4):223-7. PubMed ID: 9383424
[TBL] [Abstract][Full Text] [Related]
30. Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker.
Gilbert CW; McGowan EB; Seery GB; Black KS; Pegram MD
J Exp Ther Oncol; 2003; 3(1):27-35. PubMed ID: 12724856
[TBL] [Abstract][Full Text] [Related]
31. Direct in vivo observation of 5-fluorouracil release from a prodrug in human tumors heterotransplanted in nude mice: a magnetic resonance study.
Guerquin-Kern JL; Volk A; Chenu E; Lougerstay-Madec R; Monneret C; Florent JC; Carrez D; Croisy A
NMR Biomed; 2000 Aug; 13(5):306-10. PubMed ID: 10960921
[TBL] [Abstract][Full Text] [Related]
32. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
33. Preparation and characterization of water-soluble prodrug, liposomes and micelles of Paclitaxel.
Dhanikula AB; Panchagnula R
Curr Drug Deliv; 2005 Jan; 2(1):75-91. PubMed ID: 16305410
[TBL] [Abstract][Full Text] [Related]
34. Development of novel water-soluble photocleavable protective group and its application for design of photoresponsive paclitaxel prodrugs.
Noguchi M; Skwarczynski M; Prakash H; Hirota S; Kimura T; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 May; 16(10):5389-97. PubMed ID: 18440235
[TBL] [Abstract][Full Text] [Related]
35. Fabrication of redox-responsive doxorubicin and paclitaxel prodrug nanoparticles with microfluidics for selective cancer therapy.
Ma X; Özliseli E; Zhang Y; Pan G; Wang D; Zhang H
Biomater Sci; 2019 Jan; 7(2):634-644. PubMed ID: 30534690
[TBL] [Abstract][Full Text] [Related]
36. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.
Houba PH; Leenders RG; Boven E; Scheeren JW; Pinedo HM; Haisma HJ
Biochem Pharmacol; 1996 Aug; 52(3):455-63. PubMed ID: 8687500
[TBL] [Abstract][Full Text] [Related]
37. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters.
Lin YS; Tungpradit R; Sinchaikul S; An FM; Liu DZ; Phutrakul S; Chen ST
J Med Chem; 2008 Dec; 51(23):7428-41. PubMed ID: 19053781
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility.
Niethammer A; Gaedicke G; Lode HN; Wrasidlo W
Bioconjug Chem; 2001; 12(3):414-20. PubMed ID: 11353540
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug.
Cavallaro G; Licciardi M; Caliceti P; Salmaso S; Giammona G
Eur J Pharm Biopharm; 2004 Jul; 58(1):151-9. PubMed ID: 15207549
[TBL] [Abstract][Full Text] [Related]
40. The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug.
Song P; Yao X; Zhong T; Zhang S; Guo Y; Ren W; Huang D; Duan XC; Yin YF; Zhang SS; Zhang X
Oncotarget; 2016 Jul; 7(30):48467-48480. PubMed ID: 27366947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
